Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310277) titled 'Expanded Access to ABBV-706' on Dec. 16, 2025.
Study Type: Expanded Access
Primary Sponsor: AbbVie
Condition:
Small Cell Lung Cancer
Intervention:
Drug: ABBV-706
Recruitment Status: Not recruiting
Date of First Enrollment: October 30, 2025
To know more, visit https://clinicaltrials.gov/study/NCT07310277
Disclaimer: Curated by HT Syndication....